Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Bravaccini

Showing results (1-10 of 143) with videos related to

Pageof 15
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 19, 2019
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?Sara Bravaccini
Methods in Molecular Biology (Clifton, N.J.)|March 2, 2021
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit)Sara Bravaccini
Methods in Molecular Biology (Clifton, N.J.)|March 2, 2021
Telomerase Activity Analysis In Urine Sediment for Bladder CancerValentina Casadio, Sara Bravaccini
Breast Cancer Research : BCR|April 5, 2019
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?Sara Bravaccini, Roberta Maltoni
Journal of Personalized Medicine|November 27, 2021
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory PitfallsSara Bravaccini, Roberta Maltoni
Annals of Translational Medicine|May 9, 2022
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancerRoberta Maltoni, Sara Bravaccini
Cancer Cytopathology|September 22, 2018
Petals and thorns in programmed death-ligand 1 testing: Is all non-small cell lung cancer diagnostic material suitable?Sara Bravaccini, Giuseppe Bronte
Breast Cancer Research and Treatment|May 24, 2019
What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?Roberta Maltoni, Sara Bravaccini
Translational Lung Cancer Research|March 25, 2020
What's the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?Sara Bravaccini, Paola Ulivi
Cell Transplantation|September 10, 2020
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?Sara Bravaccini, Giovanni Martinelli, Claudio Cerchione
Pageof 15

Showing results (1-10 of 143) with videos related to

Sort By:
Pageof 15
Lung Cancer (Amsterdam, Netherlands)|March 19, 2019
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?Sara Bravaccini
Methods in Molecular Biology (Clifton, N.J.)|March 2, 2021
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit)Sara Bravaccini
Methods in Molecular Biology (Clifton, N.J.)|March 2, 2021
Telomerase Activity Analysis In Urine Sediment for Bladder CancerValentina Casadio, Sara Bravaccini
Breast Cancer Research : BCR|April 5, 2019
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?Sara Bravaccini, Roberta Maltoni
Journal of Personalized Medicine|November 27, 2021
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory PitfallsSara Bravaccini, Roberta Maltoni
Annals of Translational Medicine|May 9, 2022
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancerRoberta Maltoni, Sara Bravaccini
Cancer Cytopathology|September 22, 2018
Petals and thorns in programmed death-ligand 1 testing: Is all non-small cell lung cancer diagnostic material suitable?Sara Bravaccini, Giuseppe Bronte
Breast Cancer Research and Treatment|May 24, 2019
What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?Roberta Maltoni, Sara Bravaccini
Translational Lung Cancer Research|March 25, 2020
What's the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?Sara Bravaccini, Paola Ulivi
Cell Transplantation|September 10, 2020
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?Sara Bravaccini, Giovanni Martinelli, Claudio Cerchione
Pageof 15